| Gregory Edward Carter, MD | |
|
87 Medical Park Dr Ste A, Brevard, NC 28712-3210 | |
| (828) 883-5858 | |
| (828) 884-3339 |
| Full Name | Gregory Edward Carter |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 42 Years |
| Location | 87 Medical Park Dr Ste A, Brevard, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972618312 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME149607 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holmes Regional Medical Center | Melbourne, FL | Hospital |
| North Florida Regional Medical Center | Gainesville, FL | Hospital |
| Palm Bay Hospital | Palm bay, FL | Hospital |
| Cleveland Clinic Martin North Hospital | Stuart, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Health First Medical Group Llc | 7416100672 | 713 |
News Archive
News outlets are reporting on various policy developments — whether it's the Senate's effort to fund the federal government, ongoing legal challenges to the overhaul or a Michigan antitrust suit — that create tests for the sweeping health law. Meanwhile, however, Health and Human Services Secretary Kathleen Sebelius touts the law's benefits and warns against another challenge — that of repeal.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
› Verified 6 days ago
| Entity Name | Martin Memorial Physicians Corporation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578505228 PECOS PAC ID: 7315833555 Enrollment ID: O20040225000440 |
News Archive
News outlets are reporting on various policy developments — whether it's the Senate's effort to fund the federal government, ongoing legal challenges to the overhaul or a Michigan antitrust suit — that create tests for the sweeping health law. Meanwhile, however, Health and Human Services Secretary Kathleen Sebelius touts the law's benefits and warns against another challenge — that of repeal.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
› Verified 6 days ago
| Entity Name | Sacred Heart Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453308 PECOS PAC ID: 3779491386 Enrollment ID: O20051015000049 |
News Archive
News outlets are reporting on various policy developments — whether it's the Senate's effort to fund the federal government, ongoing legal challenges to the overhaul or a Michigan antitrust suit — that create tests for the sweeping health law. Meanwhile, however, Health and Human Services Secretary Kathleen Sebelius touts the law's benefits and warns against another challenge — that of repeal.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
› Verified 6 days ago
| Entity Name | Health First Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750626495 PECOS PAC ID: 7416100672 Enrollment ID: O20130122000135 |
News Archive
News outlets are reporting on various policy developments — whether it's the Senate's effort to fund the federal government, ongoing legal challenges to the overhaul or a Michigan antitrust suit — that create tests for the sweeping health law. Meanwhile, however, Health and Human Services Secretary Kathleen Sebelius touts the law's benefits and warns against another challenge — that of repeal.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Edward Carter, MD 4205 Belfort Rd Ste 4015, Jacksonville, FL 32216-3623 Ph: (904) 450-6063 | Gregory Edward Carter, MD 87 Medical Park Dr Ste A, Brevard, NC 28712-3210 Ph: (828) 883-5858 |
News Archive
News outlets are reporting on various policy developments — whether it's the Senate's effort to fund the federal government, ongoing legal challenges to the overhaul or a Michigan antitrust suit — that create tests for the sweeping health law. Meanwhile, however, Health and Human Services Secretary Kathleen Sebelius touts the law's benefits and warns against another challenge — that of repeal.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
› Verified 6 days ago